Effect of intravitreal bevacizumab injection in central serous chorioretinopathy

Abstract Purpose To investigate the effect of intravitreal bevacizumab injection on the type of central serous chorioretinopathy. Methods We performed a retrospective analysis of 43 patients (43 eyes) who were diagnosed with central serous chorioretinopathy and underwent intravitreal bevacizumab injection from March 2014 to March 2018. The best corrected visual acuity (BCVA) and central macular thickness (CMT) before and 3, 6, 9, and 12 months after injection were compared according to the type of central serous chorioretinopathy. The types of central chorioretinopathy were classified as acute (onest < 6 months), chronic (onest ≥ 6 months), and recurrent group. Results 43 eyes of 43 patients, 10 eyes of acute group, 21 eyes of chronic group, and 12 eyes of recurrent group. Age, sex, initial BCVA, CMT, duration of follow‐up, and the number of intravitreal bevacizumab injection were not significantly different between the three groups (p > 0.05). The BCVA (logMAR) was not significantly different between the three groups before, 3, 6, 9, and 12 months after the injection. But, at 3, 6, 9, and 12 months after injection, the BCVA of the chronic group tended to be worse than that of the acute group and the recurrent group. The CMT was not significantly different between the three groups before, 3, 6, 9, and 12 months after injection. But, at 12 months, the CMT of the chronic group tended to be larger than that of the acute group and the recurrent group. In each group, a comparison of the initial BCVA and BCVA at 12 months, initial BCVA and final BCVA, and initial CMT and CMT at 12 months showed a significant decrease in the CMT at 12 months compared to the initial CMT in the acute group (p = 0.005). There was no statistical significance in the chronic group. In the recurrent group, both the BCVA at 12 months (p = 0.007) and final BCVA (p = 0.011) improved significantly compared with the initial BCVA. The CMT was also significantly decreased at 12 months compared to the initial CMT (p = 0.006). Conclusions We concluded the effect of intravitreal bevacizumab injection on the improvement of BCVA and CMT in acute and recurrent central serous chorioretinopathy.